Page last updated: 2024-11-08

lysyl-tryptophyl-alpha-lysine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lysyl-tryptophyl-alpha-lysine: RN & N1 from 9th CI Form Index; RN given refers to (all-L)-isomer; KWK-CO2 is the positively charged oligopeptide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID161970
CHEBI ID160356
SCHEMBL ID3384748
MeSH IDM0094184

Synonyms (26)

Synonym
1JEV ,
lysyl-tryptophyl-alpha-lysine
n2-(n-l-lysyl-l-tryptophyl)-l-lysine
ccris 2594
l-lysine, n(2)-(n-l-lysyl-l-tryptophyl)-
CHEBI:160356
(2s)-6-amino-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]hexanoic acid
38579-27-0
lys-trp-lys
SCHEMBL3384748
lysyl-tryptophyl-lysine carboxylate
kwk-co2
lysyltryptophyllysine
lys-trp-lys acetate
AKOS030531735
h-lys-trp-lys-oh
CS-8122
l-lysyl-l-tryptophanyl-l-lysine
lysyl-tryptophanyl-lysine
HY-P1350
A16959
(s)-6-amino-2-((s)-2-((s)-2,6-diaminohexanamido)-3-(1h-indol-3-yl)propanamido)hexanoic acid
MS-28457
n~2~-{2-[(2,6-diamino-1-hydroxyhexylidene)amino]-1-hydroxy-3-(1h-indol-3-yl)propylidene}lysine
DTXSID00959443
(2s)-6-amino-2-[(2s)-2-[(2s)-2,6-diaminohexanamido]-3-(1h-indol-3-yl)propanamido]hexanoic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Oligo-peptide Binding ProteinSalmonella enterica subsp. enterica serovar TyphimuriumKd0.13000.13000.13000.1300AID977611
Chain A, Oligo-peptide Binding ProteinSalmonella enterica subsp. enterica serovar TyphimuriumKd0.13000.13000.13000.1300AID977611
Chain A, Oligo-peptide Binding ProteinSalmonella enterica subsp. enterica serovar TyphimuriumKd0.13000.13000.13000.1300AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1996Nature structural biology, Dec, Volume: 3, Issue:12
The role of water in sequence-independent ligand binding by an oligopeptide transporter protein.
AID1811Experimentally measured binding affinity data derived from PDB1996Nature structural biology, Dec, Volume: 3, Issue:12
The role of water in sequence-independent ligand binding by an oligopeptide transporter protein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (31.82)18.7374
1990's5 (22.73)18.2507
2000's6 (27.27)29.6817
2010's4 (18.18)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.11 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]